1. RESEARCH & INNOVATION SHOWCASE Alan Morgan, Jeff Barclay, Bob Burgoyne (Physiology) Graeme Sills, Tony Marson (Pharmacology/Walton Centre Neurology)
Epilepsy affects 1% of the population
One third of patients are resistant to current antiepileptic drugs
Existing AEDs act on a narrow range of targets
Existing AEDs inhibit seizures, not the underlying disease process
New drug discovery models needed based on epilepsy genetics
Our approach: use genetic data from patients to develop model organisms as novel drug screening platforms
Poster T12

2. RESEARCH & INNOVATION SHOWCASE Alan Morgan, Jeff Barclay, Bob Burgoyne (Physiology) Graeme Sills, Tony Marson (Pharmacology/Walton Centre Neurology)
Find epilepsy
mutations
Validate
In rodents
Screen
compounds
Mutate worm
orthologue
Marson
Sills
Human GABRB3
= worm unc-49
A B C D E F
Morgan
Barclay
Burgoyne
Sills
Poster T12

3. RESEARCH & INNOVATION SHOWCASE Alan Morgan, Jeff Barclay, Bob Burgoyne (Physiology) Graeme Sills, Tony Marson (Pharmacology/Walton Centre Neurology)
We can provide:
Novel in vivo drug discovery platform based on emerging clinical genetics
Chemical genetic approach to reveal drug molecular targets and MOA
Applicability to other neurological disorders (eg, neurodegeneration - poster)
We are seeking:
Industrial partners interested in target-based phenotypic drug screening
Poster T12